Synthetic lethality guiding selection of drug combinations in ovarian cancer.

Andreas HeinzelMaximilian MarholdPaul MayerMichael SchwarzErwin TomasichArno LukasMichael KrainerPaul Perco

Published in: PloS one (2019)

A set of drug combinations currently not tested in late stage ovarian cancer clinical trials was identified having impact on synthetic lethal interactions thus being worth of further investigations regarding their therapeutic potential in ovarian cancer.

Keyphrases

clinical trial
emergency department
randomized controlled trial
adverse drug
drug induced
open label